Evidence from basic research for opioid combinations

Expert Opinion on Drug Discovery

Volumn 7, Issue 2, 2012, Pages 165-178

  Davis, Mellar P ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

arrestin; Bias signaling; Conformation; Delta; Functional selectivity; G proteins; Heterodimer; Modulation; Mu; Opioid; Receptor; Signaling

Indexed keywords

BETA ARRESTIN 2; BUPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FENTANYL; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; HETERODIMER; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALBUPHINE; NALOXONE; NALTREXONE; OPIATE; OXYCODONE;

ALLODYNIA; ANALGESIA; ANTINOCICEPTION; BINDING SITE; CLINICAL RESEARCH; DRUG SELECTIVITY; EVIDENCE BASED PRACTICE; HUMAN; HYPERALGESIA; MEDLINE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ANALGESICS, OPIOID; ANIMALS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; LIGANDS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN; RECEPTORS, OPIOID;

EID: 84856372880     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.648611     Document Type: Review

References (161)

1. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993;16(1):1-18 (Pubitemid 23028493)
2. Pasternak GW. Molecular insights into mu opioid pharmacology: from the clinic to the bench. Clin J Pain 2010;26:(Suppl 10):S3-9
3. Raehal KM, Schmid CL, Groer CE, Bohn LM. Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 2011;63(4):1001-19
4. Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact. Br J Anaesth 2011;107(1):8-18
5. Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev 2007(4):CD003868
6. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002(1):CD003447
7. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2004(2):CD003971
8. Bolan EA, Tallarida RJ, Pasternak GW. Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 2002;303(2):557-62 (Pubitemid 35231226)
9. Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database Syst Rev 2009(3):CD002763
10. Cepeda MS, Carr DB, Miranda N, et al. Comparison of morphine, ketorolac, and their combination for postoperative pain: results from a large, randomized, double-blind trial. Anesthesiology 2005;103(6):1225-32 (Pubitemid 41692507)
11. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150(3):573-81
12. Pan YX. Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol 2005;24(11):736-50
13. Ravindranathan A, Joslyn G, Robertson M, et al. Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci USA 2009;106(26):10811-16
14. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage 2005;29(5 Suppl):S2-9 (Pubitemid 40720242)
15. Vissers KC, Besse K, Hans G, et al. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 2010;10(2):85-93
16. Xu J, Xu M, Rossi GC, et al. Identification and characterization of seven new exon 11-associated splice variants of the rat mu opioid receptor gene, OPRM1. Mol Pain 2011;7(1):9
17. Pasternak G, Pan YX. Mu opioid receptors in pain management. Acta Anaesthesiol Taiwan 2011;49(1):21-5
18. Kang HC, Jeong You S, Jae Chey M, et al. Identification of a de novo Lys304Gln mutation in the glycine receptor alpha-1 subunit gene in a Korean infant with hyperekplexia. Mov Disord 2008;23(4):610-13
19. He L, Kim JA, Whistler JL. Biomarkers of morphine tolerance and dependence are prevented by morphine-induced endocytosis of a mutant mu-opioid receptor. FASEB J 2009;23(12):4327-34
20. Kim JA, Bartlett S, He L, et al. Morphine-induced receptor endocytosis in a novel knockin mouse reduces tolerance and dependence. Curr Biol 2008;18(2):129-35
21. Bayerer B, Stamer U, Hoeft A, Stuber F. Genomic variations and transcriptional regulation of the human mu-opioid receptor gene. Eur J Pain 2007;11(4):421-7 (Pubitemid 46366768)
22. Morgan D, Cook CD, Smith MA, Picker MJ. An examination of the interactions between the antinociceptive effects of morphine and various muopioids: the role of intrinsic efficacy and stimulus intensity. Anesth Analg 1999;88(2):407-13 (Pubitemid 29070208)
23. Mercadante S, Porzio G, Fulfaro F, et al. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manage 2007;34(5):532-8 (Pubitemid 47633900)
24. Morris BJ, Herz A. Distinct distribution of opioid receptor types in rat lumbar spinal cord. Naunyn Schmiedebergs Arch Pharmacol 1987;336(2):240-3 (Pubitemid 17146116)
25. Gomes I, Jordan BA, Gupta A, et al. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci 2000;20(22):RC110
26. Rothman RB, Danks JA, Jacobson AE, et al. Morphine tolerance increases mu-noncompetitive delta binding sites. Eur J Pharmacol 1986;124(1-2):113-19 (Pubitemid 16083587)
27. Gomes I, Gupta A, Filipovska J, et al. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 2004;101(14):5135-9 (Pubitemid 38469214)
28. Hasbi A, Nguyen T, Fan T, et al. Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists. Biochemistry 2007;46(45):12997-3009 (Pubitemid 350086219)
29. Vilardaga JP, Nikolaev VO, Lorenz K, et al. Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol 2008;4(2):126-31
30. Rozenfeld R, Devi LA. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J 2007;21(10):2455-65 (Pubitemid 47230675)
31. Rozenfeld R, Abul-Husn NS, Gomez I, Devi LA. An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. ScientificWorldJournal 2007;7:64-73 (Pubitemid 350292609)
32. Rozenfeld R, Devi LA. Exploring a role for heteromerization in GPCR signalling specificity. Biochem J 2010;433(1):11-18
33. Gupta A, Mulder J, Gomes I, et al. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 2010;3(131):ra54
34. Jordan BA, Cvejic S, Devi LA. Opioids and their complicated receptor complexes. Neuropsychopharmacology 2000;23(4 Suppl):S5-S18
35. George SR, Fan T, Xie Z, et al. Oligomerization of mu-and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 2000;275(34):26128-35
36. Waldhoer M, Fong J, Jones RM, et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci USA 2005;102(25):9050-5 (Pubitemid 40881076)
37. Tsao PI, von Zastrow M. Type-specific sorting of G protein-coupled receptors after endocytosis. J Biol Chem 2000;275(15):11130-40 (Pubitemid 30212756)
38. Trapaidze N, Gomes I, Bansinath M, Devi LA. Recycling and resensitization of delta opioid receptors. DNA Cell Biol 2000;19(4):195-204 (Pubitemid 30228438)
39. Arden JR, Segredo V, Wang Z, et al. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem 1995;65(4):1636-45
40. Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 2001;32(5):829-39 (Pubitemid 34024844)
41. Trapaidze N, Keith DE, Cvejic S, et al. Sequestration of the delta opioid receptor. Role of the C terminus in agonist-mediated internalization. J Biol Chem 1996;271(46):29279-85 (Pubitemid 26382641)
42. Schiller PW, Fundytus ME, Merovitz L, et al. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem 1999;42(18):3520-6 (Pubitemid 29445087)
43. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999;399(6737):697-700 (Pubitemid 29289066)
44. Wang WW, Shahrestanifar M, Jin J, Howells RD. Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Proc Natl Acad Sci USA 1995;92(26):12436-40 (Pubitemid 26014084)
45. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007;320(1):1-13 (Pubitemid 46025713)
46. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 2007;72(6):1393-401 (Pubitemid 350146075)
47. Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 2007;28(8):407-15 (Pubitemid 47087972)
48. Kenakin T. Allosteric agonist modulators. J Recept Signal Transduct Res 2007;27(4):247-59 (Pubitemid 47450770)
49. Schuller AG, King MA, Zhang J, et al. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 1999;2(2):151-6 (Pubitemid 30491315)
50. Pan YX, Xu J, Xu M, et al. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci USA 2009;106(12):4917-22
51. Womer DE, DeLapp NW, Shannon HE. Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice. Pain 1997;70(2-3):223-8 (Pubitemid 27179635)
52. McKenzie FR, Milligan G. Delta-opioidreceptor-mediated inhibition of adenylate cyclase is transduced specifically by the guanine-nucleotide-binding protein Gi2. Biochem J 1990;267(2):391-8 (Pubitemid 20136071)
53. Hescheler J, Rosenthal W, Trautwein W, Schultz G. The GTP-binding protein, Go, regulates neuronal calcium channels. Nature 1987;325(6103):445-7 (Pubitemid 17056412)
54. Chakrabarti S, Regec A, Gintzler AR. Chronic morphine acts via a protein kinase Cgamma-G(beta)-adenylyl cyclase complex to augment phosphorylation of G(beta) and G(betagamma) stimulatory adenylyl cyclase signaling. Brain Res Mol Brain Res 2005;138(1):94-103 (Pubitemid 41032933)
55. Crain SM, Shen KF. Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends Pharmacol Sci 1998;19(9):358-65 (Pubitemid 28458832)
56. Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J. Agonists determine the pattern of G-protein activation in mu-opioid receptormediated supraspinal analgesia. Brain Res Bull 2001;54(2):229-35 (Pubitemid 32223929)
57. Garzon J, Sanchez-Blazquez P. Administration of myr(+)-G(i2)alpha subunits prevents acute tolerance (tachyphylaxis) to mu-opioid effects in mice. Neuropharmacology 2001;40(4):560-9 (Pubitemid 32209041)
58. Sanchez-Blazquez P, Juarros JL, Martinez-Pena Y, et al. Gx/z and Gi2 transducer proteins on mu/delta opioid-mediated supraspinal antinociception. Life Sci 1993;53(23):PL381-6
59. Standifer KM, Pasternak GW. G proteins and opioid receptor-mediated signalling. Cell Signal 1997;9(3-4):237-48 (Pubitemid 27271643)
60. Wheeler-Aceto H, Cowan A. Buprenorphine and morphine cause antinociception by different transduction mechanisms. Eur J Pharmacol 1991;195(3):411-13
61. Niv D, Nemirovsky A, Metzner J, et al. Antinociceptive effect induced by the combined administration of spinal morphine and systemic buprenorphine. Anesth Analg 1998;87(3):583-6 (Pubitemid 28397478)
62. Thompson CM, Wojno H, Greiner E, et al. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O-and N-demethylated metabolites at mu-and delta-opioid receptors. J Pharmacol Exp Ther 2004;308(2):547-54 (Pubitemid 38134216)
63. Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005;135(1):247-61 (Pubitemid 41219753)
64. Crain SM, Shen KF. Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. NIDA Res Monogr 1995;147:234-68
65. Shen KF, Crain SM. Biphalin, an enkephalin analog with unexpectedly high antinociceptive potency and low dependence liability in vivo, selectively antagonizes excitatory opioid receptor functions of sensory neurons in culture. Brain Res 1995;701(1-2):158-66
66. Crain SM, Shen KF. Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Neurochem Res 1996;21(11):1347-51 (Pubitemid 26397064)
67. Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 2000;84(2-3):121-31 (Pubitemid 30074213)
68. Shen KF, Crain SM. Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence. Brain Res 1994;636(2):286-97 (Pubitemid 24044646)
69. Crain SM, Shen KF. Chronic morphine-treated sensory ganglion neurons remain supersensitive to the excitatory effects of naloxone for months after return to normal culture medium: an in vitro model of 'protracted opioid dependence'. Brain Res 1995;694(1-2):103-10
70. Fan T, Varghese G, Nguyen T, et al. A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem 2005;280(46):38478-88 (Pubitemid 43853746)
71. Clark MJ, Furman CA, Gilson TD, Traynor JR. Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation. J Pharmacol Exp Ther 2006;317(2):858-64
72. Zaki PA, Keith DE Jr, Brine GA, et al. Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther 2000;292(3):1127-34 (Pubitemid 30136610)
73. Borgland SL, Connor M, Osborne PB, et al. Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 2003;278(21):18776-84 (Pubitemid 36799259)
74. Whistler JL, von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 1998;95(17):9914-19 (Pubitemid 28415269)
75. Ross FB, Wallis SC, Smith MT. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain 2000;84(2-3):421-8 (Pubitemid 30074246)
76. Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci 2011;36(9):457-69
77. Zheng H, Chu J, Qiu Y, et al. Agonist-selective signaling is determined by the receptor location within the membrane domains. Proc Natl Acad Sci USA 2008;105(27):9421-6
78. Raehal KM, Bohn LM. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 2011;60(1):58-65
79. Frolich N, Dees C, Paetz C, et al. Distinct pharmacological properties of morphine metabolites at G(i)-protein and beta-arrestin signaling pathways activated by the human mu-opioid receptor. Biochem Pharmacol 2011;81(10):1248-54
80. Clark MJ, Linderman JJ, Traynor JR. Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model. Mol Pharmacol 2008;73(5):1538-48 (Pubitemid 351574843)
81. Xie Z, Li Z, Guo L, et al. Regulator of G protein signaling proteins differentially modulate signaling of mu and delta opioid receptors. Eur J Pharmacol 2007;565(1-3):45-53 (Pubitemid 46795481)
82. Sanchez-Blazquez P, Rodriguez-Munoz M, Montero C, Garzon J. RGS-Rz and RGS9-2 proteins control mu-opioid receptor desensitisation in CNS: the role of activated Galphaz subunits. Neuropharmacology 2005;48(1):134-50 (Pubitemid 40022922)
83. Garzon J, Rodriguez-Diaz M, Lopez-Fando A, Sanchez-Blazquez P. RGS9 proteins facilitate acute tolerance to mu-opioid effects. Eur J Neurosci 2001;13(4):801-11 (Pubitemid 32174805)
84. Psifogeorgou K, Terzi D, Papachatzaki MM, et al. A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia. J Neurosci 2011;31(15):5617-24
85. Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 2011;336(2):296-302
86. Vaidehi N, Kenakin T. The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol 2010;10(6):775-81
87. Lohse MJ, Nikolaev VO, Hein P, et al. Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors. Trends Pharmacol Sci 2008;29(3):159-65
88. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 2005;4(11):919-27 (Pubitemid 41637694)
89. Wang HY, Burns LH. Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS ONE 2009;4(1):e4282
90. Zheng H, Loh HH, Law PY. Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications. IUBMB Life 2010;62(2):112-19
91. Bohn LM, Gainetdinov RR, Lin FT, et al. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000;408(6813):720-3 (Pubitemid 32015987)
92. Molinari P, Vezzi V, Sbraccia M, et al. Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem 2010;285(17):12522-35
93. Liao D, Lin H, Law PY, Loh HH. Mu-opioid receptors modulate the stability of dendritic spines. Proc Natl Acad Sci USA 2005;102(5):1725-30 (Pubitemid 40209235)
94. Yuste R. Dendritic spines and distributed circuits. Neuron 2011;71(5):772-81
95. Marie N, Lecoq I, Jauzac P, Allouche S. Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists. J Biol Chem 2003;278(25):22795-804 (Pubitemid 36830341)
96. Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 1996;48(3):413-63 (Pubitemid 126782561)
97. Costa T, Klinz FJ, Vachon L, Herz A. Opioid receptors are coupled tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell membranes. Mol Pharmacol 1988;34(6):744-54 (Pubitemid 19014395)
98. Fallon MT, Laird BJ. A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project. Palliat Med 2011;25(5):597-603
99. Millan MJ, Morris BJ, Herz A. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists. J Pharmacol Exp Ther 1988;247(2):721-8
100. Tsai RY, Tai YH, Tzeng JI, et al. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway. Neuroscience 2009;159(4):1244-56
101. Mattioli TA, Milne B, Cahill CM. Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats. Mol Pain 2010;6:22
102. Lin SL, Tsai RY, Shen CH, et al. Co-administration of ultra-low dose naloxone attenuates morphine tolerance in rats via attenuation of NMDA receptor neurotransmission and suppression of neuroinflammation in the spinal cords. Pharmacol Biochem Behav 2010;96(2):236-45
103. Lin SL, Tsai RY, Tai YH, et al. Ultra-low dose naloxone upregulates interleukin-10 expression and suppresses neuroinflammation in morphine-tolerant rat spinal cords. Behav Brain Res 2010;207(1):30-6
104. Largent-Milnes TM, Guo W, Wang HY, et al. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain 2008;9(8):700-13
105. Powell KJ, Abul-Husn NS, Jhamandas A, et al. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther 2002;300(2):588-96
106. Morinville A, Cahill CM, Esdaile MJ, et al. Regulation of delta-opioid receptor trafficking via mu-opioid receptor stimulation: evidence from mu-opioid receptor knock-out mice. J Neurosci 2003;23(12):4888-98 (Pubitemid 36793215)
107. Cahill CM, McClellan KA, Morinville A, et al. Immunohistochemical distribution of delta opioid receptors in the rat central nervous system: evidence for somatodendritic labeling and antigen-specific cellular compartmentalization. J Comp Neurol 2001;440(1):65-84
108. Abul-Husn NS, Sutak M, Milne B, Jhamandas K. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu-and delta-opioid receptor antagonists. Br J Pharmacol 2007;151(6):877-87 (Pubitemid 47075317)
109. Heyman JS, Jiang Q, Rothman RB, et al. Modulation of mu-mediated antinociception by delta agonists: characterization with antagonists. Eur J Pharmacol 1989;169(1):43-52 (Pubitemid 19244947)
110. Daniels DJ, Lenard NR, Etienne CL, et al. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci USA 2005;102(52):19208-13 (Pubitemid 43049591)
111. Golebiewska U, Johnston JM, Devi L, et al. Differential response to morphine of the oligomeric state of mu-opioid in the presence of delta-opioid receptors. Biochemistry 2011;50(14):2829-37
112. Gomes I, Ijzerman AP, Ye K, et al. G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol 2011;79(6):1044-52
113. Olmstead MC, Burns LH. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology (Berl) 2005;181(3):576-81 (Pubitemid 41480907)
114. Leri F, Burns LH. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem Behav 2005;82(2):252-62 (Pubitemid 41727934)
115. Tompkins DA, Lanier RK, Harrison JA, et al. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology (Berl) 2010;210(4):471-80
116. Hay JL, La Vincente SF, Somogyi AA, et al. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. Eur J Pain 2011;15(3):293-8
117. La Vincente SF, White JM, Somogyi AA, et al. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clin Pharmacol Ther 2008;83(1):144-52
118. Farahmand S, Ahmadi O, Dehpour A, Khashayar P. Does adding low doses of oral naltrexone to morphine alter the subsequent opioid requirements and side effects in trauma patients? Am J Emerg Med 2012;30(1):75-8
119. Cruciani RA, Lussier D, Miller-Saultz D, Arbuck DM. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Manage 2003;25(6):491-4 (Pubitemid 36629270)
120. Hamann S, Sloan PA, Witt W. Low-dose intrathecal naloxone to enhance intrathecal morphine analgesia: a case report. J Opioid Manag 2008;4(4):251-4
121. Imasogie NN, Singh S, Watson JT, et al. Ultra low-dose naloxone and tramadol/acetaminophen in elderly patients undergoing joint replacement surgery: a pilot study. Pain Res Manag 2009;14(2):103-8
122. Hamann S, Sloan P. Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study. J Opioid Manag 2007;3(3):137-44
123. Kendrick WD, Woods AM, Daly MY, et al. Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus. Anesth Analg 1996;82(3):641-7
124. Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg 2005;100(4):953-8 (Pubitemid 40409506)
125. Cepeda MS, Africano JM, Manrique AM, et al. The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain 2002;96(1-2):73-9 (Pubitemid 34270630)
126. Webster LR, Butera PG, Moran LV, et al. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006;7(12):937-46 (Pubitemid 44854737)
127. Chindalore VL, Craven RA, Yu KP, et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 2005;6(6):392-9 (Pubitemid 40804344)
128. Webster LR. Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs 2007;16(8):1277-83 (Pubitemid 47317016)
129. Lee SC, Wang JJ, Ho ST, Tao PL. Nalbuphine coadministered with morphine prevents tolerance and dependence. Anesth Analg 1997;84(4):810-15
130. Loomis CW, Penning J, Milne B. A study of the analgesic interaction between intrathecal morphine and subcutaneous nalbuphine in the rat. Anesthesiology 1989;71(5):704-10 (Pubitemid 19275091)
131. Yeh YC, Lin TF, Chang HC, et al. Combination of low-dose nalbuphine and morphine in patient-controlled analgesia decreases incidence of opioid-related side effects. J Formos Med Assoc 2009;108(7):548-53
132. Cohen SE, Ratner EF, Kreitzman TR, et al. Nalbuphine is better than naloxone for treatment of side effects after epidural morphine. Anesth Analg 1992;75(5):747-52
133. Ho ST, Wang JJ, Liu HS, et al. Comparison of PCA nalbuphine and morphine in Chinese gynecologic patients. Acta Anaesthesiol Sin 1998;36(2):65-70
134. Gordon AT, Levine JD, Dubois MY, et al. Open-label exploration of an intravenous nalbuphine and naloxone mixture as an analgesic agent following gynecologic surgery. Pain Med 2007;8(6):525-30 (Pubitemid 47316335)
135. Liao CC, Chang CS, Tseng CH, et al. Efficacy of intramuscular nalbuphine versus diphenhydramine for the prevention of epidural morphine-induced pruritus after cesarean delivery. Chang Gung Med J 2011;34(2):172-8
136. Yeh YC, Lin TF, Lin FS, et al. Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. Br J Anaesth 2008;101(4):542-8
137. Pongraweewan O, Santawata U, Weerasarn L, et al. Epidural nalbuphine for post cesarean epidural morphine induced pruritus. J Med Assoc Thai 2009;92(6):782-6
138. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997;73(2):151-7 (Pubitemid 27491675)
139. Leow KP, Smith MT. The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 1994;54(17):1229-36 (Pubitemid 24107404)
140. Nielsen CK, Ross FB, Lotfipour S, et al. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007;132(3):289-300 (Pubitemid 350051566)
141. Nielsen CK, Ross FB, Smith MT. Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. J Pharmacol Exp Ther 2000;295(1):91-9
142. Peckham EM, Traynor JR. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 2006;316(3):1195-201 (Pubitemid 43345294)
143. Koch T, Widera A, Bartzsch K, et al. Receptor endocytosis counteracts the development of opioid tolerance. Mol Pharmacol 2005;67(1):280-7 (Pubitemid 40069989)
144. Arttamangkul S, Quillinan N, Low MJ, et al. Differential activation and trafficking of micro-opioid receptors in brain slices. Mol Pharmacol 2008;74(4):972-9
145. Virk MS, Williams JT. Agonist-specific regulation of mu-opioid receptor desensitization and recovery from desensitization. Mol Pharmacol 2008;73(4):1301-8 (Pubitemid 351439212)
146. Lemberg K, Kontinen VK, Viljakka K, et al. Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg 2006;102(6):1768-74 (Pubitemid 43799854)
147. Staahl C, Upton R, Foster DJ, et al. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol 2008;48(5):619-31 (Pubitemid 351503514)
148. Staahl C, Christrup LL, Andersen SD, et al. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain 2006;123(1-2):28-36 (Pubitemid 43816754)
149. Staahl C, Dimcevski G, Andersen SD, et al. Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study. Scand J Gastroenterol 2007;42(3):383-90
150. Olesen AE, Staahl C, Arendt-Nielsen L, Drewes AM. Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study. Br J Clin Pharmacol 2010;70(2):189-200
151. Grach M, Massalha W, Pud D, et al. Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br J Clin Pharmacol 2004;58(3):235-42 (Pubitemid 39209056)
152. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003;89(11):2027-30 (Pubitemid 38030898)
153. He L, Whistler JL. An opiate cocktail that reduces morphine tolerance and dependence. Curr Biol 2005;15(11):1028-33 (Pubitemid 40772150)
154. Bobula B, Hess G. Effects of morphine and methadone treatments on glutamatergic transmission in rat frontal cortex. Pharmacol Rep 2009;61(6):1192-7
155. Kogel B, Christoph T, Strassburger W, Friderichs E. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain 2005;9(5):599-611 (Pubitemid 41219791)
156. Thomas JM, Hoffman BB. Buprenorphine prevents and reverses the expression of chronic etorphine-induced sensitization of adenylyl cyclase in SK-N-SH human neuroblastoma cells. J Pharmacol Exp Ther 1993;264(1):368-74 (Pubitemid 23309225)
157. Marquez P, Borse J, Nguyen AT, et al. The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine. Neuroscience 2008;155(3):597-602
158. Yamamoto T, Shono K, Tanabe S. Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. J Pharmacol Exp Ther 2006;318(1):206-13
159. Hao JX, Wiesenfeld-Hallin Z, Xu XJ. Lack of cross-tolerance between the antinociceptive effect of intrathecal orphanin FQ and morphine in the rat. Neurosci Lett 1997;223(1):49-52 (Pubitemid 27093017)
160. Spagnolo B, Calo G, Polgar WE, et al. Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol 2008;153(3):609-19 (Pubitemid 351199024)
161. Marquez P, Borse J, Nguyen AT, et al. The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine. Neuroscience 2008;155(3):597-602